QureTech Bio secures major investment from Kempestiftelserna

QureTech Bio has received a substantial investment from Kempestiftelserna. A total of SEK 14 million is invested in the company by Kempestiftelserna along with the company’s largest shareholder, Nascent Invest.

Umeå-based QureTech Bio is developing new solutions to combat disease-causing bacteria to tackle antimicrobial resistance (AMR).

Kempestiftelserna is two foundations committed to supporting groundbreaking research and initiatives in Västerbotten, Norrbotten, and Västernorrland. For example, in 2023, Kempestiftelserna along with Umeå University and Knut och Alice Wallenbergs Stiftelse, invested SEK 67,5 million in the Laboratory for Molecular Infection Medicine Sweden (MIMS) at Umeå University.

Alice Kempe, Chairman of the board at Kempestiftelserna, comments on the investment in QureTech Bio:

“We believe in the innovative approach of QureTech Bio and are proud to support the company’s efforts in fighting antimicrobial resistance. This partnership reflects our commitment to fostering advancements in medical research at and around Umeå University and thereby improving public health.”

The CEO of QureTech Bio, Markus Thor:

“We are happy to welcome such a reputable foundation as Kempestiftelserna as a shareholder. Their investment makes a true difference and is a testament to the importance of our work and the potential impact it can have on global health“.

Markus Thor explains that this financial support will specifically aid in targeting infectious bacteria resistant to conventional antibiotics.

”This investment will enable us to accelerate our development programs. Focusing on a completely new class of antibiotics, the company is set to make significant strides in addressing antimicrobial resistance” he says.

For more info, please contact
Markus Thor, CEO
E-mail: markus.thor@quretech.com
Telephone: +46 73-520 40 35
Web: www.quretech.com

About QureTech Bio
QureTech Bio AB (QTB) is a biotechnology company developing new solutions to combat disease-causing bacteria to tackle one of our times' greatest health threats, antimicrobial resistance (AMR). The company’s lead program is focused on developing a new class of antibiotics, called GmPcides, that are effective against multidrug-resistant Gram-positive bacteria.
QTB is located in Umeå, one of Sweden's most vibrant life science clusters.

About Kempestiftelserna
Kempestiftelserna are two foundations committed to supporting groundbreaking research and initiatives in Västerbotten, Norrbotten, and Västernorrland that have a meaningful impact on society. Through funding of academic research and, in a limited number of cases, by supporting selected strategic projects and companies, the foundations aims to foster innovation and drive progress in various fields, including healthcare, education, and technology.